S3Ab, a novel antibody targeting B lymphocytes, is a potential therapeutic agent for B-lineage malignancies-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

S3Ab, a novel antibody targeting B lymphocytes, is a potential therapeutic agent for B-lineage malignancies

Published:2019-03-11 Issue:10 Volume:27 Page:1053-1060
ISSN:1061-186X
Container-title:Journal of Drug Targeting
language:en
Short-container-title:Journal of Drug Targeting

Author:

Li Sisi¹^ORCID,Shen Hongqiang²^ORCID,Shu Qiang³

Affiliation:

1. Division of Hematology-Oncology, Children’s Hospital of Zhejiang University School of Medicine, Hangzhou, P.R. China;

2. Division of Clinical Laboratory, and Division of Hematology-Oncology, Children’s Hospital of Zhejiang University School of Medicine, Hangzhou, P.R. China;

3. Division of Cardiac Surgery, Children's Hospital of Zhejiang University School of Medicine, Hangzhou, P.R. China

Funder

Natural Scientific Fund of Zhejiang Province

National Natural Science Foundation of China

Department of Health of Zhejiang Province

Publisher

Informa UK Limited

Subject

Pharmaceutical Science

Link

https://www.tandfonline.com/doi/pdf/10.1080/1061186X.2019.1584809

Reference28 articles.

1. CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

2. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

3. Novartis Pharmaceuticals Corporation. Kymriah (tisagenlecleucel): Prescribing information. East Hanover, New Jersey, USA. 2018.

4. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP